Last €70.62 EUR
Change Today +0.75 / 1.07%
Volume 0.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 6:18 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1040 Spring Street

Silver Spring, MD 20910

United States

Phone: 301-608-9292

Fax: 301-608-9291

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions in the United States and internationally. Products Products to Treat Cardiopulmonary Diseases Pulmonary Arterial Hypertension (PAH) Remodulin: The company’s primary product for treating PAH is Remodulin, the active pharmaceutical ingredient of which is a prostacyclin analogue known as treprostinil. The company sells Remodulin to its specialty pharmaceutical distributors in the United States and to its international distributors. The United States Food and Drug Administration (FDA) initially approved Remodulin for subcutaneous (under the skin) administration. Remodulin has also been approved for subcutaneous use in various countries outside of the United States. It is also working with Medtronic, Inc. on demonstrating the safety of its Synchromed II implantable infusion pump for intravenous Remodulin. Tyvaso: The FDA approved Tyvaso is an inhaled prostacyclin therapy for the treatment of PAH. The company sells Tyvaso to the same specialty pharmaceutical distributors in the United States that distribute Remodulin. Adcirca: Adcirca is a once-daily oral therapy for the treatment of PAH. The company acquired the commercial rights to Adcirca for the treatment of PAH in the U.S. from Eli Lilly and Company. It sells Adcirca to pharmaceutical wholesalers. UT-15C Sustained Release Tablets (Oral Treprostinil) The company is developing a salt form of treprostinil for oral administration. It is in the late stages of developing its oral tablet of treprostinil diolamine for the treatment of PAH, and has commenced pre-clinical studies of a self-injectable form of treprostinil. The company’s wholly-owned subsidiary, Lung LLC, is developing beraprost, another type of prostacyclin analogue, as an oral tablet known as 314d and as an extended release injection referred to as TransCon Beraprost, both for the treatment of PAH. Self-Injectable Prostacyclin Analogues In 2012, the company signed an agreement with Ascendis Pharma A/S (Ascendis Pharma) to apply Ascendis Pharma's proprietary TransCon technology platform to its treprostinil molecule. Under this agreement, the company also intends to pursue development of a TransCon technology-enabled sustained release formulation of beraprost, which is another prostacyclin analogue. Beraprost The company has a right to develop and market a modified-release formulation of beraprost (beraprost-MR) in the United States, Canada, Mexico, South America, Europe, Egypt, India, South Africa, and Australia for the treatment of cardiovascular indications, pursuant to its license agreement with Toray Industries, Inc. Beraprost is a chemically stable, orally bioavailable prostacyclin analogue. Cell-Based Therapy In 2011, the company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize a cell-based product for the treatment of PAH using Pluristem's proprietary cell technology. The company is conducting preclinical toxicology and pharmacology studies to support a potential investigational new drug application for the treatment of PAH, and intends to commence a phase I clinical study in Australia. Products to Treat Cancer Chimeric Monoclonal Antibody 14.18 (Ch14.18) Antibody: The company has a cooperative research and development agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health to collaborate on the late-stage development and regulatory agency submissions of Ch14.18 for children with high-risk neuroblastoma and patients with other forms of cancers. Ch14.18 is an antibody that has shown potential in the treatment of various types of cancer by targeting GD2, a glycolipid on the surface of tumor cells. 8H9 Antibody: The company has an agreement with Memorial Sloan-Kettering Cancer Center, under which it has obtained various license rights to an investigational monoclonal antibody, 8H9, for the treatment of metastatic brain cancer. 8H9 is a mouse IgG1 MAb that is highly r

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €70.62 EUR +0.75

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.85.85 CHF +0.15
Alexion Pharmaceuticals Inc $149.80 USD +0.75
Celanese Corp $57.57 USD +0.55
Nippon Shinyaku Co Ltd ¥1,836 JPY +13.00
Vertex Pharmaceuticals Inc $64.17 USD -0.22
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 29.3x
Price/Sales 4.3x
Price/Book 3.8x
Price/Cash Flow 27.8x
TEV/Sales 3.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.